Kynexis
4 known investors
Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases. Its lead program is in a Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS), with expansion planned into Alzheimer's disease.
Founders & leadership
Investors · 4
In the news
Finance Watch: Venture Capital Investors Meet Biotechs In The Middleinsights.citeline.com · Aug 2026
Kynexis pockets €97m to advance cognition-focused schizophrenia drugfinance.yahoo.com · Aug 2026
Kynexis Extends Series A to €97 Million to Advance Potential First-in-Class Investigational Medicine for Cognitive Disorders - BioSpacebiospace.com · Aug 2026
Kynexis Extends Series A to €97 Million to Advance Potential First-in-Class Investigational Medicine for Cognitive Disorders | The Manila Timesmanilatimes.net · Aug 2026Frequently asked questions
- What does Kynexis do?
- Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases. Its lead program is in a Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS), with expansion planned into Alzheimer's disease.
- Who founded Kynexis?
- Kynexis was founded by Robert Schwarcz, Carol Tamminga, Christer Köhler.
- Who are Kynexis's investors?
- Kynexis's investors include Ysios Capital, Forbion, Novartis Venture Fund, Sunstone Capital.